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Purpose:  To  examine  the  association  of  age-related  macular  degeneration  (AMD)  with  HtrA  serine  peptidase  1
(HTRA1) gene rs11200638 G→A polymorphism and LOC387715/ ARMS2 gene rs10490924 G→T polymorphisms, and
to evaluate the magnitude of the gene effect and the possible genetic mode of action.
Methods: We searched the US National Library of Medicine’s PubMed, Embase, OMIM, ISI Web of Science, and CNKI
databases in a systematic manner to retrieve all genetic association studies on the HTRA1 (rs11200638) and LOC387715/
ARMS2 (rs10490924) gene polymorphisms and AMD. We performed a meta-analysis conducted with Stata software,
version 9.0.
Results: Individuals who carried the AA and AG genotypes of HTRA1 gene rs11200638 G→A polymorphism had 2.243
and 8.669 times the risk of developing AMD, respectively, when compared with those who carry the GG genotype.
Individuals carrying the TT and TG genotypes of LOC387715/ ARMS2 gene rs10490924 G→T polymorphism had 7.512
and 2.353 times the risk of developing AMD, respectively, compared with those who carry GG genotype. These results
suggested a “moderate” codominant, multiplicative genetic mode; that is, both HTRA1 rs11200638 G→A polymorphism
and LOC387715/ARMS2 rs10490924 G→T polymorphism play important roles in the pathogenesis of AMD. We found
no evidence of publication bias. Between-study heterogeneity was found in both allele-based analysis and genotype-based
analysis.
Conclusions: HTRA1 rs11200638 G→A polymorphism and LOC387715/ARMS2 rs10490924 G→T polymorphism play
important roles in AMD. Gene-gene and gene-environmental interactions, as well as precise mechanisms underlying
common variants in the HTRA1 gene and LOC387715/ ARMS2 gene, potentially increase the risk of AMD and need further
exploration.
Age-related  macular  degeneration  (AMD)  is  a
neurodegenerative disease that leads to visual impairment and
accounts  for  half  of  all  cases  of  registered  blindness  in
Western individuals older than 65 years of age [1-14]. There
are approximately eight million people in the United States
with  symptoms  of  early  or  intermediate  AMD,  of  whom
approximately  one  million  will  develop  advanced  AMD
within the next five years [15-17]. AMD is estimated to affect
about 50 million people worldwide [18-20], and an increase
in aging populations makes AMD a significant public health
concern  and  a  major  focus  of  research  efforts  (National
Advisory Council).
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AMD  is  a  clinically  heterogeneous  and  genetically
complex disease, with multiple environmental and genetic
risk factors involved [20-25]. While epidemiological studies
have linked cigarette smoking, alcohol consumption, light
exposure, diet, drugs, and high blood pressure to the risk of
AMD [19,23,26-36], familial aggregation and twin studies
[37-43] have suggested that genetic variation may also play
an important role in the disease. Although AMD has been
reported to be associated with genetic variations in the genes
of adenosine-triphosphate (ATP)-binding transporter protein
4 [44-46], apolipoprotein E [47-52], excision-repair cross-
complementing group 6 [53], fibulin 5 [54], fibulin 6 [55,
56], elongation of very-long-chain fatty acids-like 4 [57-59],
factor B/complement component 2 [60], toll-like receptor 4
[61-63], and vascular endothelial growth factor [64], recent
genome-wide linkage studies found that genomic regions at
chromosomes 1q31–32 and 10q26 may have a bigger role in
susceptibility to AMD [65]. The identification of overlapping
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1958loci  on  chromosome  1q  by  several  study  groups  [66-68]
indicates  that  this  locus  probably  harbors  a  major  AMD-
associated gene. Recently, the component factor H (CFH)
gene on chromosome 1q31 has been revealed as the first major
AMD-susceptibility gene, perhaps accounting for about 30%–
50% of AMD patients. The CFH Y402H variant in the CFH
gene has also been identified as a causal polymorphism in
studies of populations other than those of European and North
American origin [30,69-78], and a follow-up meta-analysis
[79] has confirmed this association in Western populations.
Studies in Japan, however, did not show any associations
between  CFH  Y402H  polymorphism  and  AMD  [80,81],
suggesting that there must be some other loci susceptible for
AMD.  Several  studies  have  showed  that  a  locus  at
chromosome  10q26  [82-84]  of  CFH  may  independently
contribute to AMD susceptibility [65,76,82-84]. Three genes
identified at chromosome 10q26 and associated with the risk
of AMD are Pleckstrin Homology Domain-containing Protein
Family A member 1, age-related maculopathy susceptibility
2  (LOC387715/age-related  maculopathy  susceptibility  2
[ARMS2]),  and  high-temperature  requirement  factor  A1
(HTRA1/PRSS11) [65,76,82-84]. Thus, AMD appears to be a
product  of  the  interaction  between  multiple  loci  of
susceptibility rather than a collection of single-gene disorders.
However,  the  number  of  loci  involved,  the  degree  of
attributable  risk  conferred,  and  the  interactions  between
various loci remain obscure.
The  HTRA1  gene  spans  a  53,366-base  region  on
chromosome  10q26  (124211047–124264413,  Gene  ID:
5654); it encodes a member of a family of serine proteases
expressed in both mouse and human retinas [85,86], and its
expression in human fibroblasts increases with aging [87].
HTRA1 appears to regulate the degradation of extracellular
matrix proteoglycans. This activity has been considered to
facilitate access of other degradative matrix enzymes, such as
collagenases  and  matrix  metalloproteinases,  to  their
substrates [88]. Overexpression of HTRA1 alters the integrity
of  Bruch’s  membrane,  favoring  the  invasion  of  choroid
capillaries across the extracellular matrix, as occurs in wet
AMD. HTRA1 also binds and inhibits transforming growth
factor-β  (TGF-β),  an  important  regulator  of  extracellular
matrix deposition and angiogenesis [89]. During the years
2006 to 2008, several studies were conducted to investigate
the association between HTRA1 gene polymorphisms and
AMD. A single-nucleotide polymorphism (rs11200638) in
the promoter region of the HTRA1 gene was found to be
significantly associated with susceptibility to AMD in studies
of Caucasian populations in the US [90-97], Central Europe
[98], France [99], and the UK [100]; of East Asian populations
in  China  [101-104]  and  Japan  [105-107];  and  of  Indian
populations  in  India  [108].  Another  putative  AMD-
susceptibility gene, LOC387715/ARMS2, has recently been
identified.  LOC387715/ARMS2  encodes  a  deduced  107–
amino acid protein with nine predicted phosphorylation sites
and  a  molecular  mass  of  12  kDa.  Real-time  (RT)-PCR
analysis demonstrated that LOC387715/ARMS2 transcripts
were expressed in the retina and in a variety of other tissues
and cell lines. Transfection experiments in mammalian cells
localized the protein to the mitochondrial outer membrane
[95]. Up to now, the biologic characterization of this gene has
been limited. However, Rivera et al. [109] concluded that the
A69S single-nucleotide polymorphism (rs10490924) in exon
1  of  the  LOC387715/ARMS2  gene  was  the  most  likely
susceptibility allele of AMD. Since an individual study may
not  have  sufficient  statistical  robustness  to  confirm  the
association between HTRA1 and LOC387715/ARMS2 gene
polymorphisms and AMD, we considered that a meta-analysis
that combined data from all published studies would provide
a more accurate estimate of the extent of association, leading
to  less  risk  of  false-positive  results  [110].  Thus,  we
systematically pooled the results of all available population-
based association studies of the HTRA1 rs11200638 G→A
polymorphism, the LOC387715/ARMS2 rs10490924 G→T
polymorphism,  and  AMD.  We  attempted  to  estimate  the
strength of the genetic association with AMD, as well as the
genetic  mode  of  action,  and  to  gauge  the  extent  of
heterogeneity  in  the  strength  of  the  associations  among
different studies.
METHODS
Search strategy and inclusion criteria: We searched the US
National Library of Medicine’s PubMed, Embase, OMIM, ISI
Web  of  Science,  and  Chinese  National  Knowledge
Infrastructure (CNKI) databases in a systematic manner to
retrieve  all  genetic  association  studies  on  the  HTRA1
(rs11200638)  and  LOC387715/ARMS2  (rs10490924)
polymorphisms and AMD published before April 2008. The
search strategy was based on a combination of the terms (HtrA
serine  peptidase  1  or  HTRA1),  (age-related  maculopathy
susceptibility 2 or LOC387715), and (age-related macular
degeneration  or  AMD).  The  references  of  all  computer-
identified publications were searched for additional studies,
and the PubMed option ‘‘Related Articles’’ was also used to
search  for  potentially  relevant  papers.  Searches  were
performed by two independent reviewers (B.Z. and J.Y.). We
included  all  published  articles  regardless  the  language  of
publication.
Studies were included if they met the following criteria:
1) The study reported original data from case-control or cohort
studies.  2)  The  alleles  and  genotypes  for  the  HTRA1
polymorphism (rs11200638), respectively, were A and G and
AA,  AG,  and  GG.  3)  The  alleles  and  genotypes  for  the
LOC387715/ARMS2  polymorphism  (rs10490924),
respectively, were G and T and GG, GT, and TT. 4) The
numbers of subjects possessing each allele and genotype in
the AMD and control groups were available. 5) In the case of
multiple publications from the same study group, the most
complete and recent results were used. We set no restriction
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1959on  the  source  of  controls  (general  population,  clinic,  or
hospital). For those studies where AMD was graded (e.g.,
drusen, pigment abnormalities in retinal pigment epithelium
[RPE], geographic atrophy, and choroidal neovascularization
[CNV]),  the  gradings  were  combined  into  a  single  AMD
group.
Data extraction: Data were extracted independently by two
investigators  (B.Z.  and  J.Y.),  who  used  recommended
guidelines to report on meta-analyses of observational studies
[111]. The following data were extracted from the eligible
studies: authors, journal title and year of publication, country
of origin, selection and characteristics of cases and controls,
demographic data, ethnicity of the study population (e.g.,
Caucasian or East Asian), numbers of eligible and genotyped
cases  and  controls,  and  genotype  distributions  in  cases,
controls, and available subgroups. Furthermore, we examined
whether matching had been used; whether there was specific
mention of blinding of the genotyping personnel to the clinical
status of subjects; whether the genotyping method used had
been validated; and whether genotype frequencies in control
groups  conformed  to  the  Hardy–Weinberg  equilibrium
(HWE). Any disagreement was adjudicated by a third author
(R.L.).
Statistical analysis: We used the odds ratio as the metric of
choice and this was estimated for each study. To explore the
possible  association  between  HTRA1  and  LOC387715/
ARMS2 polymorphisms and AMD, and to avoid excessive
comparisons, we calculated the odds ratio by two methods:
allele comparison (the A allele versus the G allele in the
HTRA1 rs11200638 G→A polymorphism), and comparing
the risk-variant homozygotes and heterozygotes with wild
homozygotes (i.e., AA versus GG [OR1] and AG versus GG
[OR2] in the HTRA1 rs11200638 G→A polymorphism). We
estimated and characterized the prevalence of the risk allele
with only the data from controls. When we analyzed genotype
data in the meta-analysis, zero cell counts were assigned a
fixed  value  (typically  0.5).  In  addition,  we  calculated  the
population attributable risk (PAR) of the risk allele according
to the Chang et al. [112] method.
We first compared the alleles for cases and controls to
detect  overall  differences  and  genetic  association.  Allele
frequencies  were  computed  for  studies  reporting  only
genotypic data. Pooled odds ratios were computed two times:
by the fixed effects model of Mantel and Haenszel [113], and
by  the  random  effects  model  of  DerSimonian  and  Laird
[114]. Random effects incorporated an estimate of between-
study variance and provided wider confidence intervals when
the results of the constituent studies differed. The random
effects model was more appropriate when heterogeneity was
present [115]. Unless otherwise stated, the random effects
estimates reported here were calculated by the DerSimonian
and Laird model.
Our primary genetic analysis of the HTRA1 rs11200638
G→A polymorphism, the LOC387715/ARMS2 rs10490924
G-to  -T  polymorphism,  and  AMD  was  based  on  the
comparisons  between  risk-variant  homozygotes  and
heterozygotes versus wild homozygotes so that the strength
of the genetic association and the genetic mode of action could
be  identified  exactly.  Once  an  overall  gene  effect  was
confirmed,  the  genotype  effects  and  genetic  model  were
estimated by using the genetic model-free approach suggested
by Minelli et al. [116], in which no assumptions about genetic
models are required. A multivariate meta-analysis employing
the Bayesian method [116] was used to calculate OR1 and
OR2. The logarithm (log) odds ratios were modeled on the
basis  of  both  between-  and  within-study  variations.  A
stochastic parameter lambda (λ), equal to the ratio of log
OR2 and log OR1, was also computed [115]. The parameter λ
suggested the genetic mode of action; specifically, the model
is a recessive model if λ=0, a codominant model if λ=0.5, a
dominant model if λ=1, and homozygous or heterosis model
if λ<0 or λ>1.
We examined the deviations from the HWE in control
populations for each study by using the exact method [117].
For all the analyses, we compared results between inclusion
and  exclusion  of  studies  in  Hardy–Weinberg  (HW)
disequilibrium.  In  addition,  all  studies  were  included
regardless of HWE and provided a revision of the degree of
HW disequilibrium by using the inbreeding coefficient (F)
suggested by Trikalinos et al. [118]. In brief, data in the control
group were used to assess the F value for each study. Predicted
genotype frequencies were estimated and then used to replace
the  observed  frequencies  in  the  summary  analysis  of
magnitude and the genetic model.
In  sensitivity  analysis,  we  estimated  between-study
heterogeneity across all eligible comparisons using Cochran’s
Q  statistic  [115].  We  also  reported  the  I2  statistic,  which
describes the percentage of variability in point estimates due
to  sample  heterogeneity  rather  than  sampling  error  [119,
120],  and  can  quantify  heterogeneity  irrespective  of  the
number of studies [120,121]. I2 values larger than 75% were
considered to represent a “notable” heterogeneity [120,121].
Publication bias among studies was assessed by funnel plots
[122] and cumulative meta-analysis [123]. In the analysis of
subgroups,  we  estimated  odds  ratios  according  to  racial
descent (Caucasians versus East Asians) and AMD type (wet
AMD and other subtype or combined AMD).
All analyses were conducted with Stata software, version
9.0 (StataCorp, 2005) [124], using the meta, metan, metabias,
metacum,  and  metareg  commands,  except  the  Bayesian
method of genotype-based analysis. We fitted the Bayesian
models by using Markov chain Monte Carlo methods with a
Bayesian  framework  and  performed  our  inferences  using
WinBUGS 1.4.3 (Imperial College School of Medicine at St
Mary's,  London  2003)  [125],  taking  advantage  of  its
flexibility as well as its ability to incorporate full uncertainty
across all unknown parameters. Bayesian analyses yielded
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1960credible  intervals  rather  than  confidence  intervals;  a  95%
credible interval (CrI) describes a range in which it is probable
that an unknown quantity lies within this interval. A “burn-
in” of 10,000 iterations is performed for models, followed by
50,000 iterations for parameter estimates. A p value less than
0.05 was considered statistically significant.
RESULTS
Eligible studies: A total of 29 studies were identified based
on our search strategies, of which 13 studies [95-106,108]
were eligible for inclusion in this meta-analysis; all of these
were written in English. One [101] did not report genotype
information in their paper, but online supporting materials
provided the data. Two of the studies [100,106] did not have
genotypic data, but the authors kindly sent the supplementary
information  to  us.  Sixteen  studies  were  ineligible  for  the
following reasons: six were reviews [22,24,126-129], six did
not  study  the  association  between  the  HTRA1 rs11200638
G→A polymorphism and AMD [92-94,130-132], two [90,
91]  were  duplicated  reports  of  the  most  recent  and
comprehensive one [97], and one did not have genotype data
[107].
Detailed characteristics of the 13 included studies on the
association  between  HTRA1  rs11200638  G→A
polymorphism and AMD are presented in Table 1. Among
them, six studies related to Caucasian subjects, six to East
Asians, and one to Indians. The average age of subjects ranged
from 64.0 years to 81.2 years for cases and from 64.0 years to
77.4 years for controls. Characteristics of the 13 included
studies  on  the  association  between  LOC387715/ARMS2
rs10490924 G→T polymorphism and AMD are presented in
Table 2. Among them, 14 studies related to Caucasians, three
to East Asians, and one to Indians. The average age ranged
from 60 to 79 years for cases and from 60 to 77 years for
controls. All of the eligible studies had case-control designs.
Cases in the studies were recruited from hospital patients and
controls were mainly healthy populations recruited from the
hospital or community and unrelated to cases.
Allele comparison: Data from the control groups were used to
calculate the summary allele frequency. The frequency of the
risk allele A in the HTRA1 rs11200638 G→A polymorphism
among controls was 32.33% (95% confidence interval [CI]:
26.29, 38.38), and was significantly higher in Asians than in
Caucasians (40.11% [95% CI: 35.11, 45.12] versus 23.25%
[95% CI: 18.41, 28.09], p=0.0001). The frequency of the risk
allele  T  in  the  LOC387715/ARMS2  rs10490924  G→T
polymorphism among controls was 25.17% (95% CI: 17.33,
33.00), and was also significantly higher in Asians than in
Caucasians (38.67% [95% CI: 34.63, 42.71] versus 21.62%
[95% CI: 17.41, 28.83], p=0.0000178).
All  of  the  13  studies  were  included  to  evaluate  the
association  between  the  HTRA1  rs11200638  G→A
polymorphism and AMD [95-106,108]. As shown in Figure
1A, individuals with the A allele experienced a 2.80-fold
increased risk of AMD when compared to individuals with the
G allele (random effect OR=2.910, 95% CI: 2.552, 3.318;
Q=25.769, p=0.012, I2=53.4%). The magnitude of the effect
was similar for Asians (random effect OR=2.841, 95% CI:
2.482, 3.252) and Caucasians (random effect OR=2.981, 95%
CI: 2.357, 3.370). However, there was significantly greater
between-study heterogeneity among Caucasians (Q=20.128,
p=0.001,  I2=75.2%)  than  Asians  (Q=5.636,  p=0.465,
I2=0.0%). Excluding and adjusting two studies [96,97] with
Hardy–Weinberg equilibrium did not change the results (data
not  shown).  After  appropriately  carrying  out  a  set  of
prespecified subgroups [97], a low level of between-study
heterogeneity was found (random effect OR=3.043, 95% CI:
2.725, 3.397; Q=14.318, p=0.216, I2=23.2%). We did not find
any  evidence  of  publication  bias  in  the  eligible  studies
(corrected Begg’s test z=0.43, corrected p=0.669). Figure 2
shows the cumulative meta-analysis results; they remained
significant and were consistent over time.
The  association  between  the  LOC387715/  ARMS2
rs10490924  G→T  polymorphism  and  AMD  was  also
evaluated. As shown in Figure 1B, individuals with the T
allele had a 2.734 fold increased risk of AMD when compared
to individuals with the G allele (random effect OR=2.734,
95% CI: 2.366, 3.158; Q=80.195, p=0.000, I2=78.8%). The
magnitude of the effect was similar between Asians (random
effect  OR=2.692,  95%  CI:  2.086,  3.315)  and  Caucasians
(random effect OR=2.794, 95% CI: 2.333, 3.346). There was
also  a  significant  difference  between-study  heterogeneity
among  Caucasians  (Q=73.265,  p=0.000,  I2=83.6%)  as
opposed to Asians (Q=0.481, p=0.786, I2=0.0%). Figure 3
shows the cumulative meta-analysis results; they remained
significant and were consistent over time.
Genotype  comparison:  The  genotype  frequency  of  the
HTRA1 rs11200638 G→A polymorphism between case and
control groups is presented in Table 3. The genotype effects
for AA versus GG (OR1) and AG versus GG (OR2) were
calculated for each study. The genotype frequency of the
LOC387715/ARMS2  rs10490924  G→T  polymorphism
between the case and control groups is presented in Table 4.
The genotype effects for TT versus GG (OR1) and TG versus
GG (OR2) were calculated for each study.
In our primary analysis, multivariate meta-analysis was
conducted  to  estimate  the  pooled  risk  and  there  was  a
significantly increased risk of AMD among individuals with
both homozygous variant AA genotype (Bayesian random
effect OR1=8.469, 95% CrI: 6.766, 10.710) and heterozygous
variant AG genotype (Bayesian random effect OR2=2.243,
95% CrI: 1.969, 2.559) of the HTRA1 rs11200638 G→A
polymorphism.  A  moderate  level  of  between-study
heterogeneity (Q=19.201, p=0.084, I2=37.5%) was found for
the  homozygous  AA  genotype  and  no  between-study
heterogeneity (Q=13.951, p=0.304, I2=14.0%) was found for
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1963the heterozygous AG genotype. The estimated parameter λ
was  0.378  (95%  CrI:  0.329,  0.428),  which  suggested  a
moderate  codominant  genetic  mode  of  action.  When  we
removed the two studies [96,97] with HW disequilibrium,
similar results appeared with the pooled OR1, OR2, and λ of
9.257  (95%  CrI:  7.267,  11.910),  2.334  (95%  CrI:  2.012,
2.706),  and  0.380  (95%  CrI:  0.327,  0.435),  respectively;
however,  no  significant  between-study  heterogeneity  was
Figure 1. Random-effects meta-analysis
of allele (A versus G) of the HTRA1
gene rs11200638 G→A polymorphism
and  age  related  macular  degeneration
(AMD). A: Results from random-effects
meta-analysis of allele (A versus G) of
the  HTRA1  gene  rs11200638  G→A
polymorphism and AMD. B: Results of
the random-effects meta-analysis of the
allele (T versus G) of the LOC387715/
ARMS2  gene  rs10490924  G→T
polymorphism  and  AMD.  Reference
numbers are given in parentheses. For
study details, see Table 1 and Table 2.
Molecular Vision 2010; 16:195-198<http://www.molvis.org/molvis/v16/a213> © 2010 Molecular Vision
1964found for either the homozygous AA genotype (Q=13.898,
p=0.178,  I2=28.0%)  or  the  heterozygous  AG  genotype
(Q=13.041, p=0.221, I2=23.3%). The pooled estimates also
remained  similar  after  adjusting  HW  disequilibrium  by
coefficient  F  (OR1=9.065  [95%  CrI:  7.397,  11.180],
OR2=2.306 [95% CrI: 2.039, 2.607], and λ=0.379 [95% CrI:
0.332, 0.427]).
Multivariate meta-analysis also showed that there was a
significantly increased risk of AMD among individuals with
both the homozygous variant TT genotype (Bayesian random
effect OR1=7.512, 95% CrI\: 5.703, 9.659) and heterozygous
variant TG genotype (Bayesian random effect OR2=2.353,
95%  CrI:  2.072,  2.665)  of  the  LOC387715/  ARMS2
rs10490924 G→T polymorphism. The estimated parameter
for λ was 0.426 (95% CrI: 0.387, 0.467), which suggested a
moderate codominant genetic mode of action.
For  the  HTRA1  rs11200638  G→A  polymorphism,
stratification by ethnicity indicated a considerable variation in
Figure  2.  Cumulative  random-effects
meta-analysis of allele (A versus G) of
the  HTRA1  gene  rs11200638  G→A
polymorphism and age related macular
degeneration (AMD). For study details,
see Table 3.
Figure  3.  Cumulative  random-effects
meta-analysis of allele (G versus T) of
the  LOC387715/  ARMS2  gene
rs10490924  G→T  polymorphism  and
age  related  macular  degeneration
(AMD). For study details, see Table 4.
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G
G
Nthe  size  of  effects  between  Asian  populations  (Bayesian
random effect OR1=7.100, 95% CrI: 5.325, 9.494; Bayesian
random effect OR2=2.009, 95% CrI: 1.625, 2.511; λ=0.356,
95% CrI: 0.267, 0.442) and Caucasian populations (Bayesian
random effect OR1=10.130, 95% CrI: 6.323, 0.574; Bayesian
random effect OR2=2.347, 95% CrI: 1.918, 2.910; λ=0.368,
95% CrI: 0.307, 0.434). A moderate degree of between-study
heterogeneity was found for the AA homozygous genotype
among  both  Asians  (Q=13.978,  p=0.030,  I2=57.1%)  and
Caucasians  (Q=13.203,  p=0.022,  I2=62.1%),  but  no
significant between-study heterogeneity was found for the AG
homozygous  genotype  among  either  population  (Asians:
Q=7.309,  p=0.293,  I2=17.93%;  Caucasians:  Q=5.165,
p=0.396,  I2=3.2%).  For  the  LOC387715/  ARMS2
rs10490924  G→T  polymorphism,  a  moderate  level  of
between-study  heterogeneity  was  found  for  the  TT
homozygous  genotype  among  Caucasians  (Q=45.035,
p=0.000, I2=73.8%) and for the TG heterozygous genotype
among  both  Asians  (Q=7.783,  p=0.020,  I2=74.5%)  and
Caucasians  (Q=29.790,  p=0.003,  I2=59.7%);  however,  no
significant degree of between-study heterogeneity was found
for the TT homozygous genotype among Asians (Q=1.232,
p=0.54, I2=0.0%).
Results  of  metaregression  analysis  indicated  that
classification of AMD (wet AMD versus combined AMD)
was significantly associated with log OR2 (metaregression
beta  coefficient=-0.325,  p=0.016).  We  performed
stratification analysis on wet AMD and the combined AMD
of the HTRA1 rs11200638 G→A polymorphism, and found a
considerable  difference  in  effects  between  wet  AMD
(Bayesian  random  effect  OR1=10.110,  95%  CrI:  6.998,
16.490; Bayesian random effect OR2=2.647, 95% CrI: 2.132,
3.280;  λ=0.420,  95%  CrI:  0.0.350,  0.491)  and  combined
AMD (Bayesian random effect OR1=7.087, 95% CrI: 5.284,
9.523; Bayesian random effect OR2=1.931, 95% CrI: 1.643,
2.277; λ=0.337, 95% CrI: 0.267, 0.408). This stratification
exhibited  no  between-study  heterogeneity  for  either  OR1
(Q=3.232,  p=0.664,  I2=0.0%)  or  OR2  (Q=0.890,  p=0.971,
I2=0.0%) for combined AMD, and found a moderate degree
of between-study heterogeneity for OR1 (Q=13.978, p=0.030,
I2=57.1%) and non-significant between-study heterogeneity
for  OR2  (Q=7.309,  p=0.293,  I2=17.9%)  of  the  wet  AMD
(Table 5).
We  also  performed  stratification  analysis  on  the  wet
AMD  and  combined  AMD  of  the  LOC387715/ARMS2
rs10490924 G→T polymorphism, and found a considerable
difference in effect between wet AMD (Bayesian random
effect OR1=8.567, 95% CrI: 5.509, 12.600; Bayesian random
effect  OR2=2.519,  95%  CrI:  1.983,  3.147;  λ=0.433,  95%
CrI: 0.354, 0.513) and combined AMD (Bayesian random
effect OR1=7.021, 95% CrI: 7.021; Bayesian random effect
OR2=2.285, 95% CrI: 1.921, 2.694; λ=0.428, 95% CrI: 0.382,
0.475).  This  stratification  found  no  between-study
heterogeneity for either OR1 (Q=5.391, p=0.612, I2=0.0%) or
OR2 (Q=1.024, p=0.994, I2=0.0%) for combined AMD, and
found a moderate degree of between- study heterogeneity for
OR1  (Q=14.147,  p=0.049,  I2=51.6%)  and  non-significant
between-study  heterogeneity  for  OR2  (Q=7.311,  p=0.397,
I2=4.3%) of the wet AMD (Table 5).
There was no evidence of small study bias or publication
bias for the two comparisons. For the HTRA1 rs11200638
G→A polymorphism, funnel plots for the comparisons made
for  the  AA  homozygotes  and  AG  heterozygotes  gave
corrected p=0.077 (corrected Begg’s z=1.77) and corrected
p=0.669 (corrected Begg’s z=0.43), respectively. Figure 4
shows  the  cumulative  result  of  meta-analysis  of  the  AA
homozygotes  and  AG  heterozygotes;  they  remained
significant and stayed relatively unchanged after the third
study (Figure 4A,B). Figure 5 shows the cumulative result of
meta-analysis of the TT homozygotes and TG heterozygotes
of  LOC387715/ARMS2  rs10490924  with  G→T
polymorphism;  they  remained  significant  and  relatively
unchanged after the third study.
DISCUSSION
To our knowledge, this is the first general overview of the
association  between  the  HTRA1  rs11200638  G→A
polymorphism, the LOC387715/ARMS2 rs10490924 G→T
polymorphism, and susceptibility to AMD. The results of our
meta-analysis suggest a strong association and a moderate
codominant genetic mode of action. Our primary analysis
shows that, for the HTRA1 rs11200638 G→A polymorphism,
the AA homozygotes carry an 8.5 fold increased risk of AMD,
and the AG heterozygous variants carry just a 2.5 fold increase
in  risk  when  compared  with  GG  homozygotes;  for  the
LOC387715/ARMS2 rs10490924 G→T polymorphism, the
TT homozygotes carry a 7.5 fold increased risk of AMD, and
the TG heterozygous variants carry just a 2.4 fold increase in
risk when compared with the GG homozygotes. In addition,
our allele-based analysis suggests a nearly 3.0-fold increase
in susceptibility to AMD among persons with the A allele of
the HTRA1 rs11200638 G→A polymorphism and the T allele
of the LOC387715/ARMS2 rs10490924 G→T polymorphism.
Our  findings  were  based  on  several  gene-association
studies, which include several thousand participants and were
robust in terms of all the planned and performed sensitivity
analyses. We found no evidence of publication bias or small
study  bias  by  funnel  plots  and  cumulative  meta-analysis;
moreover,  “moderate,”  “moderate,”  and  “low”  degrees  of
between-study heterogeneity were found in alleles (A versus
G), homozygotes (AA versus GG), and heterozygotes (AG
versus  GG)  of  the  association  between  the  HTRA1
rs11200638 G→A polymorphism and AMD. When HWE was
examined, 11 of the 13 studies showed no deviation and two
showed  some  deviation.  The  removal  of  the  two  HW
disequilibrium studies meant that our overall results were also
Molecular Vision 2010; 16:195-198<http://www.molvis.org/molvis/v16/a213> © 2010 Molecular Vision
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)robust; statistical adjustment for the deviations were similar
and consistent with the incipient results. The point estimate
values were closer to a codominant model after removal of the
HW disequilibrium studies and statistical adjustment for the
deviation; this suggested a multiplicative genetic mode of
action that needs to be verified by more studies, particularly
large-scale,  long-term  longitudinal  studies.  Moderate
between-study heterogeneity was also found in the alleles (T
versus G), homozygotes (TT versus GG), and heterozygotes
(TG versus GG) of the association between the LOC387715/
ARMS2  rs10490924  G→T  polymorphism  and  AMD.
However, the data we collected in this systematic review can
only support a moderate codominant genetic model with a
tight confidence interval.
The HTRA1 gene encodes a member of the trypsin family
of serine proteases [133]. The precise pathomechanism by
which  the  HTRA1  rs11200638  A  risk  allele  affects
susceptibility  to  AMD  is  still  unclear  [134,135].  The
upregulation of HTRA1 plays a detrimental role in arthritic
disease through its capacity to degrade extracellular matrices
(ECMs) directly and to upregulate the expression of matrix
metalloproteinase, which results in ECM degradation [88].
Figure  4.  Cumulative  random-effects
meta-analysis of homozygous (A: AA
versus GG) and heterozygous (B: AG
versus  GG)  genotypes  of  the  HTRA1
gene rs11200638 G→A polymorphism
and ager related macular degeneration
(AMD). For study details, see Table 3.
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1973Yang et al. [90] hypothesized that the most likely mechanism
in the involvement of rs11200638 with AMD may be the
enhancement  of  ECM  degradation  [90].  As  shown  in  the
model of laser-induced CNV [136], the destruction of the
Bruch membrane leads to CNV development [90]. Although
the  function  of  HTRA1  in  ocular  tissues  is  unclear,  it  is
reasonable  to  speculate  that  CNV  may  develop  when  the
Bruch  membrane  is  exposed  to  the  detrimental  effects  of
HTRA1.  In  vitro,  higher  luciferase  expressions  have  been
reported in both ARPE19 and HeLaS3 cells transfected with
the HTRA1 rs1120638 risk homozygote (AA) genotype when
compared to the wild-type (GG) [101]. It has been suggested
that the presence of the HTRA1 rs11200638 A risk allele may
alter  the  affinity  of  transcription  factors,  including  the
adaptor-related protein complex 2 alpha and serum response
factor  to  the  HTRA1  promoter  [101].  Another  potential
mechanism by which the HTRA1 rs11200638 A allele may
increase AMD risk is its ability to bind to TGF-β family
members and to inhibit signaling of TGF-β family proteins,
such  as  bone  morphogenetic  protein  2  and  bone
Figure  5.  Cumulative  random-effects
meta-analysis of homozygous (A: TT
versus GG) and heterozygous (B: GT
versus GG) genotypes of LOC387715/
ARMS2  gene  rs10490924  G→T
polymorphism and age related macular
degeneration (AMD). For study details,
see Table 4.
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1974morphogenetic  protein  4),  which  have  previously  been
reported to act as negative growth regulators in RPE [89,
137].
Although  an  association  between  the  HTRA1
rs11200638  G→A  polymorphism  and  AMD  was  found,
Kanda and others [95] considered that the rs11200638 G→A
polymorphism of the HTRA1 gene did not make a major
contribution to regulation of the HTRA1 gene and there is no
association between HTRA1 G→A polymorphism and AMD.
To  verify  these  conclusions,  they  generated  mammalian
expression constructs carrying three different lengths of the
normal HTRA1 promoter (WT-long, -medium, and -short)
and the mutant sequence carrying the AMD-risk allele at the
single nucleotide polymorphism (SNP) rs11200638 (SNP-
long and -medium), and these constructs were transfected into
human  embryonic  kidney293  (HEK293),  human-derived
retinal  pigment  epithelial  (ARPE19),  and  Human
retinoblastoma (Y79) cells. As a result, they found that WT
and variant SNPs of the HTRA1 promoter activities did not
show  significant  differences  in  the  luciferase  reporter
expression, and the WT-short promoter (not including the
rs11200638 region) showed higher transcriptional activities
than the others. A further quantitative analysis provided no
evidence for significant change of mRNA expression between
control and AMD retinas. This finding contrasts with the
previous original experiment, which suggested an increase in
HTRA1 expression in lymphocytes from AMD patients [90,
127]. Taken together, these studies seem to draw a conflicting
conclusion to those of the other studies in our meta-analysis.
Localization of the LOC387715/ARMS2 protein to the
mitochondrial  outer  membrane  in  transfected  mammalian
cells suggests intriguing mechanisms through which an A69S
change may influence AMD susceptibility. Mitochondria are
implicated  in  the  pathogenesis  of  other  age-related
neurodegenerative  diseases,  including  Alzheimer  disease,
Parkinson  disease,  and  so  on  [138].  Mitochondrial
dysfunction associated with aging can result in impairment of
the  energy  metabolism  and  homeostasis,  generation  of
reactive oxygen species, accumulation of somatic mutations
in  mitochondrial  DNA,  and  activation  of  the  apoptotic
pathway  [139-141].  Decreased  number  and  size  of
mitochondria, loss of cristae, or reduced matrix density are
observed  in  AMD  retinas  compared  with  controls,  and
mitochondrial  DNA  deletions  and  cytochrome  c  oxidase-
deficient cones accumulate in the aging retina, particularly in
the  macular  region  [140,142].  Moreover,  mutations  in
mitochondrial  proteins  (e.g.,  dynamin-like  guanosine
triphosphatase  [GTPase]  optic  atrophy  1  [OPA1])  are
associated  with  optic  neurodegenerative  disorders  [143].
Photoreceptors  and  RPE  contain  high  levels  of
polyunsaturated fatty acids and are exposed to intense light
and near-arterial levels of oxygen, providing considerable risk
for oxidative damage [143,144]. Kanda and others therefore
propose that the altered function of the putative mitochondrial
protein LOC387715/ARMS2 by A69S substitution increases
the  susceptibility  to  the  aging-associated  generation  of
macular photoreceptors [95]. However, they did not observe
any  significant  difference  in  the  expression,  stability,  or
localization of the A69S variant LOC387715/ARMS2 protein
in mammalian cells. It is plausible that the A69S alteration
modifies the function of the LOC387715/ARMS2 protein by
affecting its conformation and/or interaction. For this reason,
additional analysis of the LOC387715/ARMS2 protein with
Ala or Ser codon 69 and its function in vivo are needed to
better understand its contribution to AMD pathogenesis.
Even though the results presented here are contradictory,
the  A  allele  of  the  HTRA1  gene  rs11200638  G→A
polymorphism  is  reasonably  common,  with  an  allele
frequency of over 30% in a control population and over 40%
in an Asian control population, and the T allele frequency of
the  LOC387715/ARMS2  rs10490924  G→T  polymorphism
was 25.17% in a control population and 38.67% in Asians.
This means that the effect at the population level, especially
for  Asian  populations,  could  be  quite  important.  The
proportion  of  AA  and  AG  genotypes  of  the  HTRA1
rs11200638 G→A polymorphism in a control population is
48% and the pooled OR for these two genotypes is 3.13. These
two data were 64.07, 3.47 and 39.81, 3.07 for Asians and
Caucasians,  respectively.  For  the  LOC387715/ARMS2
rs10490924 G→T polymorphism, the proportion of TT and
GT  genotypes  in  a  control  population  is  38.89%  and  the
pooled OR for these two genotypes is 3.05. These two data
were 64.00, 3.17 and 35.40, 3.13 for Asians and Caucasians,
respectively.
The PAR for the combined genotypes AA and AG of the
HTRA1 rs11200638 G→A polymorphism is 56.0% (63.5%
for  Asians,  48.4%  for  Caucasians,  61.3%  for  wet  AMD,
51.1%  for  combined  AMD).  The  PAR  for  the  combined
genotypes  TT  and  GT  of  LOC387715/ARMS2  gene
rs10490924 G→T polymorphism is 47.9% (55.4% for Asians,
44.1%  for  Caucasians,  56.8%  for  wet  AMD,  42.4%  for
combined AMD). In other words, the HTRA1 rs11200638
G→A polymorphism is involved in over half of all cases of
AMD, quite close to the previous estimate of the first major
AMD-susceptibility allele, CFH Y402H (58.9%) [79]. The
LOC387715/ARMS2 rs10490924 G→T polymorphism is also
involved in nearly half of all AMD cases. Higher PAR can
explain part of why both these genes (HTRA1 rs11200638
G→A polymorphism and LOC387715/ARMS2 rs10490924
G→T  polymorphism)  play  important  roles  in  AMD,
especially for wet AMD populations.
In  conclusion,  this  Human  Genome  Epidemiology
(HuGE) systematic review presents strong evidence for an
association  between  the  HTRA1  rs11200638  G→A
polymorphism,  LOC387715/ARMS2  rs10490924  G→T
polymorphism, and AMD, and suggests that both of these
genes play important roles in this disease. Potential gene-gene
Molecular Vision 2010; 16:195-198<http://www.molvis.org/molvis/v16/a213> © 2010 Molecular Vision
1975and  gene-environmental  interactions  and  possible
mechanisms of AMD are also summarized and discussed. Our
findings suggest that these genetic variations may serve as
biomarkers enabling the diagnosis of AMD in a more efficient
and  economical  way.  However,  large-scale,  long-term
longitudinal  studies  are  required  to  substantiate  and
strengthen this association.
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